Tag: systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease that results in increased morbidity and mortality. Under certain conditions, patients with SLE may be admitted to the intensive care unit (ICU) secondary to infectious disease flare-ups or other non-SLE disease conditions that are aggravated by SLE.
02.10.2019
 
Autoimmune connective tissue diseases are clinically variable, making biomarkers desirable for assessing future disease risk, supporting early and accurate diagnosis, monitoring disease activity and progression, selecting therapeutics and assessing treatment response.
02.08.2019
 
Specific differences in cancer risk have been observed between systemic lupus erythematosus (SLE) patients and the general population. In past decades, various studies have investigated the relationship between SLE and malignancy.
18.06.2019
 
Systemic lupus erythematosus (SLE), presenting with new onset or worsening neuropsychiatric (NP) symptoms, is a challenge in clinical practice. Mimickers such as infections, drug-induced side effects, metabolic abnormalities, malignancies, and alcohol-related disorders have to be excluded, before attributing the manifestations to disease activity
15.06.2019
 
Specific differences in cancer risk have been observed between systemic lupus erythematosus patients and the general population. Although meta-analyses have estimated cancer incidence in systemic lupus erythematosus patients, results have been inconclusive.
25.03.2019
 
Cannabidiol is a non-psychotropic component of cannabis sativa. Known to induce an immunomodulatory effect, cannabidiol’s therapeutic properties have been explored in a number of autoimmune diseases.
11.03.2019
 
Specific differences in cancer risk have been observed between systemic lupus erythematosus (SLE) patients and the general population. In past decades, various studies have investigated the relationship between SLE and malignancy
20.02.2019
 
Bioinformatics analysis of differentially expressed gene profiles associated with systemic lupus erythematosus
01.07.2018
 
No association between the risk of breast cancer and systemic lupus erythematosus: evidence from a meta-analysis
18.01.2018
 
Studies from other countries have reported an incidence of remission and LLDAS more comparable to our’s than to Zen et al's suggesting than in disadvantaged SLE populations, LLDAS may be an alternative, yet not the ideal, treatment target.
18.01.2018
 
1